QNRX Quoin Pharmaceuticals Ltd - ADR
13,453
$0.7651
$0.0051
(0.67%)
| Watchers | 13,453 |
| 52-Wk Low | $0.6029 |
| 52-Wk High | $12.00 |
| Market Cap | $2.9M |
| Volume | 39,533.00 |
| 52-Wk High | $12.00 |
| 52-Wk Low | $0.6029 |
Q4 2023 Quoin Pharmaceuticals Ltd Earnings Call TranscriptGuruFocus • 2 months ago
Related Stocks: NAS:QNRX...
Share to Feed
Company reported positive initial clinical data for QRX003 from first six evaluable subjects in ongoing open-label Netherton Syndrome study with positive benefits observed across a number of clinical...
ASHBURN, Va., March 07, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin ), a clinical stage specialty pharmaceutical company focused on rare and orphan...
Regenxbio, Quoin Pharmaceuticals, Renalytix among healthcare movers...
ASHBURN, Va., March 05, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the Company or Quoin ), a specialty pharmaceutical company focused on rare and orphan diseases, today...
Vivani Medical, Altamira Therapeutics, Quoin Pharmaceuticals among healthcare movers...
Titoli in rialzo
Il titolo Quoin Pharmaceuticals (NASDAQ:QNRX) salito del 129,59% a 6,36 dollari durante la sessione pre-market di luned .
Le azioni di Renalytix (NASDAQ:RNLX) hanno guadagnato il...
Acciones al alza
Quoin Pharmaceuticals (NASDAQ:QNRX) crecieron un 129,95% para establecerse en los 6,37 d lares durante la sesi n del pre-market del lunes.
Ainos (NASDAQ:AIMD) experimentaron un...
Clearance to include teen patients in both the company's open label and placebo controlled studies expected to significantly expand the number of eligible subjects, potentially expedite recruitment...
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ('Skinvisible') (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin...